Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1989;37(6):609-11.
doi: 10.1007/BF00562554.

Humoral and cellular effects of the K(+)-channel activator cromakalim in man

Affiliations
Clinical Trial

Humoral and cellular effects of the K(+)-channel activator cromakalim in man

P Lijnen et al. Eur J Clin Pharmacol. 1989.

Abstract

The effect of cromakalim, a K(+)-channel activator, on the plasma renin-angiotensin-aldosterone system, catecholamines and alpha-atrial natriuretic peptide, and on the intraerythrocyte concentration and transmembrane fluxes of Na+ and K+ has been investigated in 18 normal male subjects, in a double-blind parallel study. After a run-in period on placebo for 1 week, the subjects were treated either with placebo (n = 6) or cromakalim (n = 12) for 1 week. Plasma renin activity was significantly increased during cromakalim. No effect of cromakalim on plasma angiotensin II, aldosterone, adrenaline, noradrenaline and alpha-atrial natriuretic peptide was demonstrated. The intra-erythrocyte K+ concentration was decreased during cromakalim administration and Ca2(+)-dependent K(+)-channels in red blood cells were increased.

PubMed Disclaimer

Similar articles

References

    1. Klin Wochenschr. 1980 Jan 2;58(1):37-42 - PubMed
    1. Clin Chim Acta. 1978 Mar 15;84(3):305-14 - PubMed
    1. Biochem Pharmacol. 1988 Nov 1;37(21):4105-10 - PubMed
    1. Clin Chim Acta. 1984 Jun 13;139(3):321-33 - PubMed
    1. Naunyn Schmiedebergs Arch Pharmacol. 1986 Oct;334(2):202-9 - PubMed

Publication types

LinkOut - more resources